Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Go back to Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
(NASDAQ: PLRZ) Delayed: 10.66 --0 (-0%)
Previous Close $10.66    52 Week High
Open $10.66    52 Week Low
Day High $10.66    P/E N/A 
Day Low $10.66    EPS
Volume 1,014